Azetukalner, a Novel, Potent KV7 Potassium Channel Opener in Development for the Treatment of Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures, and Major Depressive Disorder

IF 6.9 2区医学 Q1 CLINICAL NEUROLOGY

Neurotherapeutics Pub Date : 2025-07-01 DOI:10.1016/j.neurot.2025.e00648

Christopher Kenney M.D.

引用次数: 0

查看原文本刊更多论文

Azetukalner，一种新型、有效的KV7钾通道打开剂，用于治疗局灶性癫痫发作、原发性全身性强直-阵挛性癫痫发作和重度抑郁症

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurotherapeutics 医学-神经科学

CiteScore

11.00

自引率

3.50%

发文量

154

审稿时长

6-12 weeks

期刊介绍： Neurotherapeutics® is the journal of the American Society for Experimental Neurotherapeutics (ASENT). Each issue provides critical reviews of an important topic relating to the treatment of neurological disorders written by international authorities. The Journal also publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field. Neurotherapeutics ® delivers a multidisciplinary perspective on the frontiers of translational neuroscience, provides perspectives on current research and practice, and covers social and ethical as well as scientific issues.